Cart
sales@molnova.com
Home - Products - Others - Other Targets - Troxipide

Troxipide

CAS No. 30751-05-4

Troxipide( BRN0493078 | Troxipide | Troxipida | Troxipidum )

Catalog No. M13981 CAS No. 30751-05-4

Troxipide is a novel systemic non-antisecretory gastric cytoprotective agent with anti-ulcer, anti-inflammatory and mucus secreting properties irrespective of pH of stomach or duodenum.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
100MG 45 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock
Get Quotation Bulk Inquiry Add to Cart

Biological Information

  • Product Name
    Troxipide
  • Note
    Research use only, not for human use.
  • Brief Description
    Troxipide is a novel systemic non-antisecretory gastric cytoprotective agent with anti-ulcer, anti-inflammatory and mucus secreting properties irrespective of pH of stomach or duodenum.
  • Description
    Troxipide is a novel systemic non-antisecretory gastric cytoprotective agent with anti-ulcer, anti-inflammatory and mucus secreting properties irrespective of pH of stomach or duodenum.(In Vitro):Troxipide exerts inhibitory, therapeutic and preventive effects to specifically those in the stomach by enhancing gastric mucosal blood flow and gastric mucosal defense factors and promoting tissue repair, blood circulation, metabolism and GU repair.(In Vivo):Troxipide (40 mg/kg; iv) significantly alleviates gastric ulcer (GU).Troxipide (40 mg/kg; iv) has a T1/2 of 210 min and 428.73 min for NCG and GUG rat, respectively.
  • In Vitro
    Troxipide exerts inhibitory, therapeutic and preventive effects to specifically those in the stomach by enhancing gastric mucosal blood flow and gastric mucosal defense factors and promoting tissue repair, blood circulation, metabolism and GU repair.
  • In Vivo
    Troxipide (40 mg/kg; iv) significantly alleviates gastric ulcer (GU). Troxipide (40 mg/kg; iv) has a T1/2 of 210 min and 428.73 min for NCG and GUG rat, respectively. Animal Model:Normal control group (NCG) and gastric ulcer group (GUG) rat (5% acetic acid 10 mL/kg/day) Dosage:10, 20, 40, 60 mg/kg Administration:Oral; daily; 2 weeks Result:The levels of these cytokines (IL-17, IL-6, TNF-α, IFN-γ and AP-1) were significantly reduced, suggesting that GU was significantly alleviated.Animal Model:NCG and GUG rat Dosage:40 mg/kg for iv Administration:IV Result:Had a T1/2 of 210 min and 428.73 min for NCG and GUG rat, respectively.
  • Synonyms
    BRN0493078 | Troxipide | Troxipida | Troxipidum
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    Inflammation/Immunology
  • Indication
    ——

Chemical Information

  • CAS Number
    30751-05-4
  • Formula Weight
    294.35
  • Molecular Formula
    C15H22N2O4
  • Purity
    >98% (HPLC)
  • Solubility
    Ethanol: 3 mg/mL (10.19 mM); DMSO: 18 mg/mL (61.15 mM)
  • SMILES
    O=C(NC1CNCCC1)C2=CC(OC)=C(OC)C(OC)=C2
  • Chemical Name
    3,4,5-trimethoxy-N-(piperidin-3-yl)benzamide

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Kusugami K, et al. Dig Liver Dis, 2000, 32(4), 305-31
Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog
related products

  • ROSIRIDIN

    Rosiridin has cardioprotective activity.

  • L-655708

    L-655708 is a selective and highly potent GABAA receptor reverse agonist with a Ki value of 0.45 nM.

  • MC1742

    MC1742 is an inhibitor of class I histone deacetylases (HDACs; IC50s = 0.1, 0.11, 0.02, and 0.61 μM for HDAC1, -2, -3, and -8, respectively) and class IIb HDACs (IC50s = 7 and 40 nM for HDAC6 and HDAC10, respectively).

Sign In Join Free